investors & media
NASDAQ: (common stock)
Data Provided by Refinitiv. Minimum 15 minutes delayed.
89% of evaluable patients (17/19) with transfusion-dependent β-thalassemia who do not have a β 0 /β 0 genotype achieved transfusion independence with 11.9 g/dL median weighted average total hemoglobin (Hb) level in HGB-207 Data from exploratory analyses of HGB-207 show improved markers of bloodRead more
99.5% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with a history of VOCs and ACS (n=14) who had at least six months follow-up At up to 24 months, no reports of serious VOC or ACS in Group C patients (n=18) with at least six monthsRead more
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 3, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, to support the health and well-being of its directors, employees and stockholders, theRead more